Experimental · 5/10
Tesofensine
Tesofensine is a small-molecule triple monoamine reuptake inhibitor that produced strong Phase 2 weight loss for obesity, about 9 to 11 percent at 24 weeks per Astrup 2008, roughly double the obesity drugs of its era. The catch is the mechanism: it raises heart rate, development stalled over cardiovascular and mood concerns, the pivotal paper carries a journal Expression of Concern, and there is no Phase 3 obesity approval. Read the full breakdown →
The prediction game
Where does Tesofensine go in 12 months?
Lock a call and say how sure you are. Right and confident earns the most; a leaderboard spot is the prize. No money, no stakes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Be the first scout on record for Tesofensine. Permanent credit on this page, plus points when your call resolves.
One call per intervention. It locks the moment you submit (no edits, no cancels) and resolves in 12 months. See the scout leaderboard →
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
Same as above — one verification covers all your entries here.
For education only, not medical advice. Supplements, peptides, and protocols can interact with medications and conditions. Talk to a qualified clinician before starting anything here.